Cellular angiofibroma of vulva was first described in 1997; a twenty-two year old female with a large mass of vulva for two years was managed successfully by simple excision with no evidence of reccurrence for a follow-up period of three years.
{"title":"Cellular angiofibroma of the vulva","authors":"S. Saichandran, V. Koothan, S. Ghose","doi":"10.5580/296c","DOIUrl":"https://doi.org/10.5580/296c","url":null,"abstract":"Cellular angiofibroma of vulva was first described in 1997; a twenty-two year old female with a large mass of vulva for two years was managed successfully by simple excision with no evidence of reccurrence for a follow-up period of three years.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90591545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 65 year old lady with no relevant past medical history was diagnosed in February 2006 with stage 3c ovarian adenocarcinoma. She underwent laparotmy, total abdominal hysterectomy, bilateral salpingo oophorectomy, omentectomy and intra peritoneal catheter insertion. It was noted in surgery there was widespread peritoneal disease. She made a slow recovery and in May 2006 she commenced the first of 6 cycles of intra peritoneal carboplatin. Post chemotherapy she was in clinical remission with no reoccurrence of symptoms and CA-125 was 32. She was doing well nine months post chemotherapy with normal examination and CA-125 of 19.
{"title":"Ovarian cancer and dermatomyositis.","authors":"A. Choudry, Gurjeet Pamma, M. Ali","doi":"10.5580/2785","DOIUrl":"https://doi.org/10.5580/2785","url":null,"abstract":"A 65 year old lady with no relevant past medical history was diagnosed in February 2006 with stage 3c ovarian adenocarcinoma. She underwent laparotmy, total abdominal hysterectomy, bilateral salpingo oophorectomy, omentectomy and intra peritoneal catheter insertion. It was noted in surgery there was widespread peritoneal disease. She made a slow recovery and in May 2006 she commenced the first of 6 cycles of intra peritoneal carboplatin. Post chemotherapy she was in clinical remission with no reoccurrence of symptoms and CA-125 was 32. She was doing well nine months post chemotherapy with normal examination and CA-125 of 19.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"141 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86253505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 63-year-old female with stage IIIA breast cancer was treated in our department with adjuan chemotherapy containing 5fluoruracil,epirubicine and cyclophosphamide. Clinical and anamnetic findings revealed no signs of any disorder and physical examination was unremarkable. The patient received, 5fluoruracil 720 mg/m 2 , epirubicine 145mg/m and cyclophosphamide 720 mg/m administered as a infusion on day one, repeated every three weeks. Treatment given on day 1 was preceded by dexametasone 4 mg i.v. and granisetron 3 mg i.v. for the prophylaxis of nausea and vomiting. The same anti-emetic treatment was repeated i.v.on day 2 and orally on days 3 and 4. The first treatment cycle was uneventful. Four days after administration of the second cycle the patient was admitted to our clinic with hand-foot syndrome(HFS), associated with nail changes on hand (hyperpigmentation) and maculopapuler eruptions on the trunk(Figure 1,2,3,4 and 5).
{"title":"Hand- Foot Syndrome And Cutaneous Reactıons Followıng Fırst Dose Of Chemotherapy","authors":"M. Yıldırım, B. Karabulut","doi":"10.5580/1a1e","DOIUrl":"https://doi.org/10.5580/1a1e","url":null,"abstract":"A 63-year-old female with stage IIIA breast cancer was treated in our department with adjuan chemotherapy containing 5fluoruracil,epirubicine and cyclophosphamide. Clinical and anamnetic findings revealed no signs of any disorder and physical examination was unremarkable. The patient received, 5fluoruracil 720 mg/m 2 , epirubicine 145mg/m and cyclophosphamide 720 mg/m administered as a infusion on day one, repeated every three weeks. Treatment given on day 1 was preceded by dexametasone 4 mg i.v. and granisetron 3 mg i.v. for the prophylaxis of nausea and vomiting. The same anti-emetic treatment was repeated i.v.on day 2 and orally on days 3 and 4. The first treatment cycle was uneventful. Four days after administration of the second cycle the patient was admitted to our clinic with hand-foot syndrome(HFS), associated with nail changes on hand (hyperpigmentation) and maculopapuler eruptions on the trunk(Figure 1,2,3,4 and 5).","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89207502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Despite having a well established role in the treatment of locally advanced rectal cancer neoadjuvant radiotherapy is associated with various acute but usually self limited side effects, which can be occasionally severe thus outweighing the potential benefits.Method: We present a case of 51-year old male who experienced a spontaneous rectal perforation after neoadjuvant radiotherapy for transmural (T3) rectal cancer located 8cms from anal verge. Clinical circumstances were highly suggestive of acute radiation toxicity leading to tumor perforation. To our knowledge, such a complication of radiotherapy is extremely rare, albeit known with only few cases reported in English literature.Conclusion: Rectal cancer perforation, albeit rare, is a dangerous early complication of neo-adjuvant radiotherapy for transmural rectal cancer which may be worthy of consideration and discussion with the patient when commencing treatment. Role of prophylactic diverting colostomy in such patients with cancer above peritoneal reflection remains an open question which needs to be redressed by further studies.
{"title":"Rectal Cancer Perforation: A Rare Complication Of Neo-Adjuvant Radiotherapy For Rectal Cancer","authors":"A. Khan, Y. Suhaibani, A. Sharief","doi":"10.5580/1889","DOIUrl":"https://doi.org/10.5580/1889","url":null,"abstract":"Purpose: Despite having a well established role in the treatment of locally advanced rectal cancer neoadjuvant radiotherapy is associated with various acute but usually self limited side effects, which can be occasionally severe thus outweighing the potential benefits.Method: We present a case of 51-year old male who experienced a spontaneous rectal perforation after neoadjuvant radiotherapy for transmural (T3) rectal cancer located 8cms from anal verge. Clinical circumstances were highly suggestive of acute radiation toxicity leading to tumor perforation. To our knowledge, such a complication of radiotherapy is extremely rare, albeit known with only few cases reported in English literature.Conclusion: Rectal cancer perforation, albeit rare, is a dangerous early complication of neo-adjuvant radiotherapy for transmural rectal cancer which may be worthy of consideration and discussion with the patient when commencing treatment. Role of prophylactic diverting colostomy in such patients with cancer above peritoneal reflection remains an open question which needs to be redressed by further studies.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86928063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mervyn Correia, D. Amonkar, Y. Dias, A. Ramani, G. Kamat, Mallidu Shashidar
Cystosarcoma phyllodes is an uncommon neoplasm of the breast, constituting 0.3 �0.9% of all breast tumors. The incidence of malignant phyllodes tumor is even lower. The tumor is similar to fibroadenoma in structure, but it is distinguished from it histologically by large leaf-like projections of stroma with increased stromal cellularity [1] . Although surgical removal is the mainstay of treatment, the extent of surgery required (excision vs. mastectomy) and the need for additional local therapy, such as radiotherapy, are unclear [2] . We report a case of a 35 year old married woman who presented to our out patient department with a fungating, foul smelling mass in the right breast that turned out to be a malignant phyllodes tumour. The malignant variant of the cystosarcoma phllodes tumour is indeed a very rare mammary tumour.
{"title":"Fungating malignant phyllodes tumour- Still a reality in this day and age !!!","authors":"Mervyn Correia, D. Amonkar, Y. Dias, A. Ramani, G. Kamat, Mallidu Shashidar","doi":"10.5580/129f","DOIUrl":"https://doi.org/10.5580/129f","url":null,"abstract":"Cystosarcoma phyllodes is an uncommon neoplasm of the breast, constituting 0.3 �0.9% of all breast tumors. The incidence of malignant phyllodes tumor is even lower. The tumor is similar to fibroadenoma in structure, but it is distinguished from it histologically by large leaf-like projections of stroma with increased stromal cellularity [1] . Although surgical removal is the mainstay of treatment, the extent of surgery required (excision vs. mastectomy) and the need for additional local therapy, such as radiotherapy, are unclear [2] . We report a case of a 35 year old married woman who presented to our out patient department with a fungating, foul smelling mass in the right breast that turned out to be a malignant phyllodes tumour. The malignant variant of the cystosarcoma phllodes tumour is indeed a very rare mammary tumour.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77348277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We describe a 60-year-old patient with symptoms of chest pain, chronic non-productive cough, generalised malaise and weight loss for four years. Bilateral interstitial infiltrates were observed radiologically. Bronchoscopy with bronchoalveolar lavage (BAL) came back positive for Mycobacterium Xenopi. She was treated with rifampin, ethambutol and azithromycin for 6 months but no clinical improvement. She became progressively dyspneic and subsequently had a Video-assisted thorascopic surgery (VATS) and histological examination of lung biopsy revealed replacement of normal lung parenchyma with diffuse infiltration of monotonous cells with scanty cytoplasma and little nuclear irregularity. In immunohistochemical examination it was detected that the LCA and B cell markers of the cells were stained positive for CD20 and CD79; whereas epithelial markers were stained negative for cytokeratin and EMA, and T cell markers were stained negative for CD3. The molecular path revealed Ig heavy chain gene clonal rearrangement consistent with neoplastic proliferation of the B-cell lineage. These features were compatible with the diagnosis of primary pulmonary BALT (bronchus-associated lymphoid tissue) lymphoma or BALTOMA. We recommend that BALTOMA should be included in the differential diagnosis of patients with slow-progressing nonspecific pulmonary symptoms and radiographic interstitial infiltrates. Biopsy under CT guidance or VATS provides sufficient tissue in peripheral lung lesions for immunologic studies to assist in diagnosis.
{"title":"A case of B-cell lymphoma of Bronchus-Associated Lymphoid Tissue (BALTOMA) masquerading as an atypical interstitial pneumonia","authors":"H. Shaaban, A. Ko, J. Sensakovic, G. Guron","doi":"10.5580/275b","DOIUrl":"https://doi.org/10.5580/275b","url":null,"abstract":"We describe a 60-year-old patient with symptoms of chest pain, chronic non-productive cough, generalised malaise and weight loss for four years. Bilateral interstitial infiltrates were observed radiologically. Bronchoscopy with bronchoalveolar lavage (BAL) came back positive for Mycobacterium Xenopi. She was treated with rifampin, ethambutol and azithromycin for 6 months but no clinical improvement. She became progressively dyspneic and subsequently had a Video-assisted thorascopic surgery (VATS) and histological examination of lung biopsy revealed replacement of normal lung parenchyma with diffuse infiltration of monotonous cells with scanty cytoplasma and little nuclear irregularity. In immunohistochemical examination it was detected that the LCA and B cell markers of the cells were stained positive for CD20 and CD79; whereas epithelial markers were stained negative for cytokeratin and EMA, and T cell markers were stained negative for CD3. The molecular path revealed Ig heavy chain gene clonal rearrangement consistent with neoplastic proliferation of the B-cell lineage. These features were compatible with the diagnosis of primary pulmonary BALT (bronchus-associated lymphoid tissue) lymphoma or BALTOMA. We recommend that BALTOMA should be included in the differential diagnosis of patients with slow-progressing nonspecific pulmonary symptoms and radiographic interstitial infiltrates. Biopsy under CT guidance or VATS provides sufficient tissue in peripheral lung lesions for immunologic studies to assist in diagnosis.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84615210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. M. Biswal, N. R. N. Idris, Zulmi Wan, W. Ismail, A. S. Halim
Overview: Radiotherapy is an important adjuvant modality in the management of extremity soft-tissue tumors. Interstitial brachytherapy implantation is a precise technique of delivering radiation that conforms to the tumor bed. Materials and Method:Selected extremity soft-tissue sarcomas were managed with wide-excision followed by preoperative implantation of brachytherapy catheters. The implant was irradiated 3-5 th day post-surgery to a dose of 3Gy BID for 3-5 days using high dose rate (HDR) system. Further additional external radiotherapy dose of 40- 50Gy in conventional fractionation was delivered to the tumor bed. Observations: 17 patients with soft tissue sarcoma were treated from 2001 to 2007.The median age of patient was 26 years (4-74 years) with male to female ratio of 12:5. Three out of 17 patients develop local recurrence and 7-patient relapse as lung metastases. At the time of reporting, 2-year local control rate was 88% and 24 month overall survival rate was 50%. The complication was minimal and manifested as subcutaneous fibrosis, pigmentation and wound dehiscence. Conclusions: Perioperative interstitial brachytherapy is an option of radiotherapy for better local control in high grade large volume and recurrent soft-tissue tumor. Proper case selection and optimal multidisciplinary management could improve survival in future.
{"title":"Peri-Operative Brachytherapy In Soft-Tissue Sarcomas. Hospital USM Experience","authors":"B. M. Biswal, N. R. N. Idris, Zulmi Wan, W. Ismail, A. S. Halim","doi":"10.5580/47f","DOIUrl":"https://doi.org/10.5580/47f","url":null,"abstract":"Overview: Radiotherapy is an important adjuvant modality in the management of extremity soft-tissue tumors. Interstitial brachytherapy implantation is a precise technique of delivering radiation that conforms to the tumor bed. Materials and Method:Selected extremity soft-tissue sarcomas were managed with wide-excision followed by preoperative implantation of brachytherapy catheters. The implant was irradiated 3-5 th day post-surgery to a dose of 3Gy BID for 3-5 days using high dose rate (HDR) system. Further additional external radiotherapy dose of 40- 50Gy in conventional fractionation was delivered to the tumor bed. Observations: 17 patients with soft tissue sarcoma were treated from 2001 to 2007.The median age of patient was 26 years (4-74 years) with male to female ratio of 12:5. Three out of 17 patients develop local recurrence and 7-patient relapse as lung metastases. At the time of reporting, 2-year local control rate was 88% and 24 month overall survival rate was 50%. The complication was minimal and manifested as subcutaneous fibrosis, pigmentation and wound dehiscence. Conclusions: Perioperative interstitial brachytherapy is an option of radiotherapy for better local control in high grade large volume and recurrent soft-tissue tumor. Proper case selection and optimal multidisciplinary management could improve survival in future.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"256 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76355831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pindborg tumour or calcifying epithelial odontogenic tumor (CEOT) is a rare and benign odontogenic neoplasm that was first described by a Dutch pathologist Jens Jorgen Pindborg in 1955. The most common clinical manifestation of CEOT is that of a localized, slow growing hard tissue swelling of the posterior jaws. Radiographically, it presents as a mixed radiolucentradiopaque lesion. Though the histopathological presentation is quite distinct, cases have been reported to show slight variations from the usual picture. One such rare variant is the presence of abundant clear cells intermixed with the tumor cells. The significance of this variant is that it has been shown to have a more aggressive behaviour with greater tendency to recur if inadequately removed. We report a case of clear cell variant of CEOT with an uncommon site of presentation in the anterior mandible.
{"title":"Clear Cell Variant Of Pindborg’s Tumor In Anterior Mandible: Case Study And Overview Of Other Histological Variants.","authors":".R Sudhakar, .N Vezhavendhan, M. Devi","doi":"10.5580/45a","DOIUrl":"https://doi.org/10.5580/45a","url":null,"abstract":"Pindborg tumour or calcifying epithelial odontogenic tumor (CEOT) is a rare and benign odontogenic neoplasm that was first described by a Dutch pathologist Jens Jorgen Pindborg in 1955. The most common clinical manifestation of CEOT is that of a localized, slow growing hard tissue swelling of the posterior jaws. Radiographically, it presents as a mixed radiolucentradiopaque lesion. Though the histopathological presentation is quite distinct, cases have been reported to show slight variations from the usual picture. One such rare variant is the presence of abundant clear cells intermixed with the tumor cells. The significance of this variant is that it has been shown to have a more aggressive behaviour with greater tendency to recur if inadequately removed. We report a case of clear cell variant of CEOT with an uncommon site of presentation in the anterior mandible.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"148 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83403881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Management of chronic myeloid leukemia (CML) during pregnancy can be difficult for patients, their families and care providers. Treatment of CML and pregnancy remains a clinical challenge. Current recommendations, for women of childbearing potential, are to use adequate contraception and avoid pregnancy while taking kinase inhibitors. Consequences of exposure to kinase inhibitors to a fetus during pregnancy are unknown. Treatment may result in an increased risk of serious fetal abnormalities or spontaneous abortion. Lack of treatment for CML, during a pregnancy, may result in disease progression. In the absence of detailed information, difficulty arises to guide this patient through a decision making process. Patients who wish to interrupt therapy and become pregnant should receive intense counseling for both parents, using the most recent data available. Decisions concerning patients with CML and pregnancies must be based on individual cases. This report describes a 25 year old woman with newly diagnosed CML who purposefully arranged harvesting and storage of her unfertilized ova, prior to commencing bosutinib chemotherapy for CML
{"title":"Planned Pregnancy for a Patient with Chronic Myeloid Leukemia","authors":"P. Ault, J. Cortes","doi":"10.5580/bea","DOIUrl":"https://doi.org/10.5580/bea","url":null,"abstract":"Management of chronic myeloid leukemia (CML) during pregnancy can be difficult for patients, their families and care providers. Treatment of CML and pregnancy remains a clinical challenge. Current recommendations, for women of childbearing potential, are to use adequate contraception and avoid pregnancy while taking kinase inhibitors. Consequences of exposure to kinase inhibitors to a fetus during pregnancy are unknown. Treatment may result in an increased risk of serious fetal abnormalities or spontaneous abortion. Lack of treatment for CML, during a pregnancy, may result in disease progression. In the absence of detailed information, difficulty arises to guide this patient through a decision making process. Patients who wish to interrupt therapy and become pregnant should receive intense counseling for both parents, using the most recent data available. Decisions concerning patients with CML and pregnancies must be based on individual cases. This report describes a 25 year old woman with newly diagnosed CML who purposefully arranged harvesting and storage of her unfertilized ova, prior to commencing bosutinib chemotherapy for CML","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75695175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shalini Ravi-Kumar, Sang-Joon Lee, I. Rabinowitz, C. Verschraegen
INTRODUCTION: Metastatic prostate cancer is lethal in 15 % of the patients. Ethnic variations in response to docetaxel in patients with metastatic prostate cancer have not been studied. The aim of this study was to identify ethnic differences in the response to docetaxel, among patients with castration resistant metastatic prostate cancer.PATIENTS AND METHODS: We queried the New Mexico Cancer Registry then the electronic charts of all castration resistant metastatic prostate cancer patients who were treated with docetaxel between 1999 and 2010 at the University of New Mexico Cancer Center. Patient characteristics that might influence the response to docetaxel such as age, prior treatment including hormones, chemotherapy, radiotherapy, and surgery, concurrent chemotherapy, site of disease, baseline PSA, and number of docetaxel courses were recorded. Progression of disease after start of treatment was defined as identification of new lesions or a biochemical recurrence. The primary end point was overall survival. Secondary end points were progression-free survival and PSA response to docetaxel. RESULTS: Despite a lower incidence of prostate cancer in NM, the death rate is higher than the national average. Although not statistically significant, the overall survival for patients treated with docetaxel is highest among Non Hispanic Whites, followed by Native Americans and worst among the Hispanic population. The progression free survival was greatest in the Native American population followed by Non Hispanic Whites, followed by Hispanics. Compared to published data, the survival of New Mexicans with prostate cancer treated with docetaxel is worse.CONCLUSION: Hispanic males with castration resistant metastatic prostate cancer on docetaxel, tended to have the lowest overall survival and progression free survival, but overall the differences between New Mexican ethnicities were not statistically significant.
{"title":"Does Ethnicity Influence Response To Docetaxel Based-Chemotherapy For Patients With Castration Resistant Prostate Cancer? The New Mexico Perspective.","authors":"Shalini Ravi-Kumar, Sang-Joon Lee, I. Rabinowitz, C. Verschraegen","doi":"10.5580/107e","DOIUrl":"https://doi.org/10.5580/107e","url":null,"abstract":"INTRODUCTION: Metastatic prostate cancer is lethal in 15 % of the patients. Ethnic variations in response to docetaxel in patients with metastatic prostate cancer have not been studied. The aim of this study was to identify ethnic differences in the response to docetaxel, among patients with castration resistant metastatic prostate cancer.PATIENTS AND METHODS: We queried the New Mexico Cancer Registry then the electronic charts of all castration resistant metastatic prostate cancer patients who were treated with docetaxel between 1999 and 2010 at the University of New Mexico Cancer Center. Patient characteristics that might influence the response to docetaxel such as age, prior treatment including hormones, chemotherapy, radiotherapy, and surgery, concurrent chemotherapy, site of disease, baseline PSA, and number of docetaxel courses were recorded. Progression of disease after start of treatment was defined as identification of new lesions or a biochemical recurrence. The primary end point was overall survival. Secondary end points were progression-free survival and PSA response to docetaxel. RESULTS: Despite a lower incidence of prostate cancer in NM, the death rate is higher than the national average. Although not statistically significant, the overall survival for patients treated with docetaxel is highest among Non Hispanic Whites, followed by Native Americans and worst among the Hispanic population. The progression free survival was greatest in the Native American population followed by Non Hispanic Whites, followed by Hispanics. Compared to published data, the survival of New Mexicans with prostate cancer treated with docetaxel is worse.CONCLUSION: Hispanic males with castration resistant metastatic prostate cancer on docetaxel, tended to have the lowest overall survival and progression free survival, but overall the differences between New Mexican ethnicities were not statistically significant.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77275175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：